Devices and Electrode Technology
In electroporation-based therapy the drug is not the only determinant of outcome: the electric field distribution in the tissue matters just as much. That distribution is set jointly by electrode geometry, inter-electrode distance, applied voltage and the tissue’s own conductivity. The corpus holds 12 technical/device studies and 79 modelling studies.
Principal Systems in Clinical Use
The platforms most frequently cited in the corpus’s device literature
| System | Manufacturer | Field of use | Distinguishing feature |
|---|---|---|---|
| Cliniporator | IGEA (Italy) | RE-ECT: superficial and subcutaneous tumours | The system on which the ESOPE standard was defined; works with type I–III electrodes and records current and voltage for every pulse. |
| Cliniporator VITAE | IGEA (Italy) | RE-ECT: deep-seated tumours | Treats deep organ lesions under imaging guidance with long, variable-geometry needle electrodes, delivering a higher output voltage. |
| NanoKnife | AngioDynamics (USA) | IRE-ECT: non-thermal ablation | ECG-synchronised high-voltage pulses, typically delivered through 2–6 needle electrodes arranged to surround the target volume. |
Why Is Field Distribution Critical?
Electroporation is threshold-based: for a cell’s membrane to become permeable, the field strength at its own location must exceed the threshold. Where the field stays below it, the drug cannot enter and that volume counts as untreated.
The practical goal is therefore to cover the whole tumour and its safety margin with a supra-threshold field. In thick or irregular lesions this is achieved by overlapping electrode applications.
Tissue conductivity is not homogeneous: fat, muscle, tumour and bone differ, and the field bends at those boundaries. For deep-seated tumours this brings patient-specific treatment planning into play: the field distribution is computed by finite-element methods on a tissue model derived from imaging, and electrode positions follow from it.
Most of the modelling studies in the corpus address exactly this problem, the calculation that runs from electrode placement to field distribution.
Parameters Monitored by the Device
| Parameter | What it does | Clinical meaning |
|---|---|---|
| Current measurement | The current drawn on each pulse is recorded | A lower-than-expected current indicates poor electrode contact or insufficient tissue conductivity |
| Voltage verification | Applied voltage is set according to electrode spacing | Target field strength (V/cm) is obtained by dividing voltage by inter-electrode distance |
| Impedance monitoring | Tissue impedance changes over the pulse train | A drop in impedance is an indirect indicator that the tissue has become permeabilised |
| ECG synchronisation | Pulses are timed to the refractory period | Used to reduce arrhythmia risk near the heart and in IRE-ECT |
Related Literature
Direct access to records on devices, electrodes and field distribution